For example, SRGN was shown to regulate TGF-β2 signaling in breast cancer, activate the NF-κB pathway in non-small lung cancer, participate in mitogen-activated protein kinase (MAPK)/β-catenin signaling in nasopharyngeal cancer and regulate the PI3K, Rac, and Src signaling pathways in breast cancer48–51. This evidence concerns the gene AKT1 and nasopharyngeal carcinoma.